Drug
Phase 2 Low Dose Myobloc
Phase 2 Low Dose Myobloc: highest development phase Phase 2/3, developed by Supernus Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Supernus Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Phase 2; Low Dose MYOBLOC (10,000 Units) NCT04815967 | Phase 2/3 | Spasticity |
| Phase 2; Low Dose MYOBLOC (15,000 Units) NCT04099667 | Phase 2/3 | Spasticity |
Latest
No recent events.
Follow Phase 2 Low Dose Myobloc on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.